Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have received an average rating of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $81.6667.

Several equities analysts have weighed in on ARWR shares. Bank of America increased their target price on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Royal Bank Of Canada upped their price target on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. B. Riley Financial increased their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Chardan Capital lifted their price objective on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Finally, Morgan Stanley boosted their price objective on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a report on Wednesday, January 7th.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 10,000 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $64.19, for a total value of $641,900.00. Following the completion of the transaction, the insider owned 236,958 shares of the company’s stock, valued at $15,210,334.02. The trade was a 4.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Tsfg LLC bought a new position in Arrowhead Pharmaceuticals during the fourth quarter worth about $25,000. First Horizon Corp bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth about $32,000. WPG Advisers LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 384.8% in the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 431 shares in the last quarter. Hantz Financial Services Inc. raised its position in shares of Arrowhead Pharmaceuticals by 177.1% during the fourth quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 471 shares during the period. Finally, Elyxium Wealth LLC acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $54,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $61.03 on Monday. The firm has a fifty day moving average of $62.31 and a two-hundred day moving average of $54.91. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. The stock has a market capitalization of $8.55 billion, a price-to-earnings ratio of 39.89 and a beta of 1.26. Arrowhead Pharmaceuticals has a 52 week low of $9.57 and a 52 week high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The company had revenue of $264.03 million during the quarter, compared to the consensus estimate of $225.66 million. During the same quarter in the prior year, the business earned ($1.39) earnings per share. The firm’s revenue for the quarter was up 10461.3% on a year-over-year basis. As a group, equities research analysts predict that Arrowhead Pharmaceuticals will post -2.42 EPS for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.